既製ウイルス
既製コントロールウイルス、AAVセロタイプテストパネル、AAVウイルス様粒子(空カプシド)などに使用されている、VectorBuilderの研究用既製ウイルスを活用することで、遺伝子デリバリーはより簡単になります。ウイルスパッケージングを専門とする当社の高タイターで高品質な既製ウイルスは、実験における高い信頼性を保証します。直感的に操作できるベクターデザインスタジオでベクターを設計し、ダウンストリームのウイルスパッケージングを追加することでカスタムウイルスを注文いただけます。
特長
高品質、高タイターのウイルス
- 実験検証済み
- 厳密なQC(タイター測定、無菌試験)
様々なウイルスシステムで提供
- レンチウイルス、AAV、アデノウイルスから蛍光レポーターを発現
- AAVセロタイプテストパネルとウイルス様粒子による実験条件の最適化
迅速かつ簡単な注文
- 数回のクリックでウイルスと容量を選択
- 数日で出荷可能
リソース
引用文献 関連文書 お客様の声
Featured Citations
Glioblastoma remodelling of human neural circuits decreases survival
Saritha Krishna, et al.
Nature, 2023, doi: 10.1038/s41586-023-06036-1
Products used:
Abstract: Gliomas synaptically integrate into neural circuits. Previous research has demonstrated bidirectional interactions between neurons and glioma cells, with neuronal activity driving glioma growth and gliomas increasing neuronal excitability. Here we sought to determine how glioma-induced neuronal changes influence neural circuits underlying cognition and whether these interactions influence patient survival. Using intracranial brain recordings during lexical retrieval language tasks in awake humans together with site-specific tumour tissue biopsies and cell biology experiments, we find that gliomas remodel functional neural circuitry such that task-relevant neural responses activate tumour-infiltrated cortex well beyond the cortical regions that are normally recruited in the healthy brain. Site-directed biopsies from regions within the tumour that exhibit high functional connectivity between the tumour and the rest of the brain are enriched for a glioblastoma subpopulation that exhibits a distinct synaptogenic and neuronotrophic phenotype. Tumour cells from functionally connected regions secrete the synaptogenic factor thrombospondin-1, which contributes to the differential neuron–glioma interactions observed in functionally connected tumour regions compared with tumour regions with less functional connectivity. Pharmacological inhibition of thrombospondin-1 using the FDA-approved drug gabapentin decreases glioblastoma proliferation. The degree of functional connectivity between glioblastoma and the normal brain negatively affects both patient survival and performance in language tasks. These data demonstrate that high-grade gliomas functionally remodel neural circuits in the human brain, which both promotes tumour progression and impairs cognition.
>See more<Collapse Fructose-1, 6-bisphosphatase is a nonenzymatic safety valve that curtails AKT activation to prevent insulin hyperresponsiveness
Li Gu, et al.
Cell Metabolism, 2023, doi: 10.1016/j.cmet.2023.03.021
Products used:
Abstract: Insulin inhibits gluconeogenesis and stimulates glucose conversion to glycogen and lipids. How these activities are coordinated to prevent hypoglycemia and hepatosteatosis is unclear. Fructose-1,6-bisphosphatase (FBP1) is rate controlling for gluconeogenesis. However, inborn human FBP1 deficiency does not cause hypoglycemia unless accompanied by fasting or starvation, which also trigger paradoxical hepatomegaly, hepatosteatosis, and hyperlipidemia. Hepatocyte FBP1-ablated mice exhibit identical fasting-conditional pathologies along with AKT hyperactivation, whose inhibition reversed hepatomegaly, hepatosteatosis, and hyperlipidemia but not hypoglycemia. Surprisingly, fasting-mediated AKT hyperactivation is insulin dependent. Independently of its catalytic activity, FBP1 prevents insulin hyperresponsiveness by forming a stable complex with AKT, PP2A-C, and aldolase B (ALDOB), which specifically accelerates AKT dephosphorylation. Enhanced by fasting and weakened by elevated insulin, FBP1:PP2A-C:ALDOB:AKT complex formation, which is disrupted by human FBP1 deficiency mutations or a C-terminal FBP1 truncation, prevents insulin-triggered liver pathologies and maintains lipid and glucose homeostasis. Conversely, an FBP1-derived complex disrupting peptide reverses diet-induced insulin resistance.
>See more<Collapse Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis
Chang Cui, et al.
Cell, 2021, doi: 10.1016/j.cell.2021.04.016
Products used:
Abstract: Cancer cell genetic variability and similarity to host cells has stymied development of broad anti-cancer therapeutics. Our innate immune system evolved to clear genetically diverse pathogens and limit host toxicity; however, whether/how innate immunity can produce similar effects in cancer is unknown. Here, we show that human, but not murine, neutrophils release catalytically active neutrophil elastase (ELANE) to kill many cancer cell types while sparing non-cancer cells. ELANE proteolytically liberates the CD95 death domain, which interacts with histone H1 isoforms to selectively eradicate cancer cells. ELANE attenuates primary tumor growth and produces a CD8+ T cell-mediated abscopal effect to attack distant metastases. Porcine pancreatic elastase (ELANE homolog) resists tumor-derived protease inhibitors and exhibits markedly improved therapeutic efficacy. Altogether, our studies suggest that ELANE kills genetically diverse cancer cells with minimal toxicity to non-cancer cells, raising the possibility of developing it as a broad anti-cancer therapy.
>See more<Collapse